MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platform Realigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing